Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parecoxib for postoperative anxiety and cognitive function after pancreatoduodenectomy
ChiCTR1900024336Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of parecoxib in anxiety disorder and cognitive disorder (CD) (2 arms), sponsored by The Second Hospital of Hebei Medical University. Primary endpoints: State-Trait Anxiety Inventory (STAI) score and Montreal Cognitive Assessment (MoCA) score. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
parecoxib
03
Conditions
anxiety disordercognitive disorder (CD)
Beyond the preview
Go deeper on ChiCTR1900024336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024336.